DaVita stock (US23918K1088): Q1 beat and raised guidance lift shares

DaVita shares rallied after Q1 2026 earnings beat expectations with 6% revenue growth, raised full-year guidance and strong cash flow in kidney care.

DaVita stock surged following the release of first-quarter 2026 results that exceeded expectations. The kidney care provider reported revenue of $3.42 billion, up 6% from the prior year, alongside net income of $197.53 million, according to ad-hoc-news as of May 11, 2026. The company also raised its full-year guidance, signaling confidence in sustained demand for dialysis services.

Shares of DaVita traded around 198.65 USD on May 11, 2026, up from 196.26 USD at the previous close on the New York Stock Exchange (NYSE: DVA), per Robinhood as of May 11, 2026. This followed a 23.46% intraday gain to 193.88 USD on earnings day, reflecting investor optimism.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: DaVita Inc.
• Sector/industry: Healthcare, kidney care and dialysis services
• Headquarters/country: United States
• Home exchange/listing venue: New York Stock Exchange (NYSE), ticker DVA
• Trading currency: USD

DaVita: core business model

DaVita operates as a leading provider of kidney care services in the United States, primarily through its network of dialysis centers. The company treats patients with chronic kidney failure, offering dialysis treatments and related healthcare services. This model relies on long-term patient relationships and reimbursement from government programs like Medicare, which account for a significant portion of revenue.

DaVita's integrated approach includes outpatient dialysis clinics, inpatient hospital services, and ancillary offerings such as pharmacy and laboratory services. The company serves approximately 250,000 patients annually across more than 2,800 centers, positioning it as a key player in the US dialysis market.

Main revenue and product drivers for DaVita

Core revenue stems from dialysis treatments, with patient volume and treatment rates as primary drivers. In Q1 2026, revenue grew through modest volume gains and improved operating margins, as noted in recent results published May 2026, according to ad-hoc-news as of May 11, 2026. Government reimbursements and private insurance payments form the bulk of inflows.

Additional drivers include value-based care programs and international operations, though the US market dominates. Strong cash flow generation, highlighted in the latest quarterly report, supports operational investments and debt management.

Industry trends and competitive position

The kidney care sector faces pressures from regulatory changes, rising costs, and an aging population driving demand for dialysis. DaVita competes with Fresenius Medical Care in a duopolistic US market, holding substantial share through its clinic network. Recent earnings underscore resilience amid reimbursement reforms.

Why DaVita matters for US investors

DaVita's exposure to the US healthcare system, particularly Medicare-dependent kidney care, ties its performance to domestic policy and demographics. Listed on the NYSE, it offers US investors a pure play on chronic disease management, with relevance amplified by the 800,000-plus Americans living with end-stage renal disease.

Conclusion

DaVita's Q1 2026 earnings beat, guidance raise, and share rally highlight operational strength in kidney care. Investors note robust revenue growth and cash flow amid a stable patient base. The company remains a focal point for those tracking US healthcare providers, with ongoing regulatory dynamics in focus.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.